Hui-hua Y. Hsiao

100 Tzyou Road, 807, 
Kaohsiung, KHQ, TW 
100 Tzyou Road, 807, 
Kaohsiung, KHQ, TW 

Overview

Hui-hua Hsiao practices practicing medicine in Kaohsiung, Taiwan.

Their clinical expertise encompasses Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 106 peer reviewed articles and participating in 2 clinical trials.

Locations

100 Tzyou Road, 807, Kaohsiung, KHQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab Paclitaxel, S1, Leucovorin, Oxaliplatin
Study Phase: Phase 2
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Bendamustine, Rituximab
Study Phase: Phase 3
View 1 Less Clinical Trial

106 Total Publications

Response to Comments on: Guillain-Barre Syndrome With Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation.
Response to Comments on: Guillain-Barre Syndrome With Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation.
Journal: The Kaohsiung journal of medical sciences
Published: June 09, 2026

Frequently Asked Questions about Hui-hua Y. Hsiao

Is Hui-hua Y. Hsiao a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Hui-hua Y. Hsiao is classified as an Experienced expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hui-hua Y. Hsiao participate in research or clinical trials?

Yes. Hui-hua Y. Hsiao has published 106 articles and abstracts on conditions like Leukemia. You can view a list of Hui-hua Y. Hsiao's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hsiao's expertise for a condition
ConditionClose
        View All 31 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile